Crinetics Pharmaceuticals, Inc. reported its financial results for the third quarter of 2025, revealing a revenue of $143,000, a significant increase from zero revenue in the same quarter of the previous year. For the nine months ending September 30, 2025, the company generated $1.54 million in revenue, up 48% from $1.04 million during the same period in 2024. Despite this revenue growth, Crinetics continued to experience substantial operating losses, reporting a net loss of $130.1 million for the third quarter, compared to a loss of $76.8 million in the prior year. The accumulated deficit as of September 30, 2025, reached $1.29 billion, reflecting a 36% increase from $952.1 million at the end of 2024.
The company's operating expenses surged, with research and development costs rising by 46% to $90.5 million in the third quarter, driven by increased clinical trial activities and headcount. Selling, general, and administrative expenses more than doubled to $52.3 million, primarily due to higher personnel costs and outside services related to the commercialization of its lead product, PALSONIFY™. The total operating expenses for the quarter amounted to $142.7 million, a 63% increase compared to the same period in 2024.
Crinetics achieved a significant milestone with the FDA's approval of PALSONIFY for the treatment of acromegaly on September 25, 2025. The company is also pursuing regulatory approval in Europe, with the European Medicines Agency validating its marketing authorization application. The company has identified a potential market of approximately 36,000 individuals in the U.S. with acromegaly, of which many remain undiagnosed or untreated. This approval is expected to enhance the company's market presence and drive future revenue growth.
As of September 30, 2025, Crinetics had $110.9 million in cash and cash equivalents, a decrease of 58% from $264.5 million at the end of 2024. The company also held $981.4 million in investment securities, down 10% from $1.09 billion. The total cash, cash equivalents, and investment securities amounted to $1.09 billion, providing a cushion for the company to fund its operations for at least the next 12 months. However, Crinetics anticipates continued operating losses as it invests in the commercialization of PALSONIFY and the development of its pipeline products, which may require additional capital through equity offerings or collaborations in the future.
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals is a clinical-stage biotech focused on developing oral, nonpeptide therapeutics targeting peptide GPCRs for endocrine diseases and tumors. Its pipeline includes treatments for acromegaly, carcinoid syndrome, and other hormonal disorders, emphasizing improved efficacy, safety, and patient convenience. The company leverages expertise in endocrine pathways, with proprietary molecules designed to address unmet medical needs in endocrinology and oncology markets.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.